Kimberly-Clark Corporation · KMB · FY2025 Q3 · Calendar Q4 2025

KMB: Innovation and premiumization support share gains

The supplied analysis supports a constructive but conditional view: innovation, premiumization, digital and club-channel growth, and potential cost relief provide support for the operating trajectory, while competition, tariffs, promotional spending and consumer pressure could limit margin and growth durability.

Reported Before market openNASDAQConsumer Defensive $32.34B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.82 Consensus $1.75
EPS surprise +4.0% Reported versus consensus
Reported revenue $4.13B Consensus $4.09B
Revenue surprise +0.9% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +3.0% Event window
SPY move -1.1% Same window
Abnormal move +4.1% Stock minus SPY
Volume 2.0× Versus trailing sessions
Subsequent drift -9.2% Up to 20 sessions
KMBSPY benchmark

Ask FN2 about KMB FY2025 Q3

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The current analysis emphasizes continued volume-plus-mix growth, diaper share gains, a Q4 promotion shift, and expected cost support from tariff mitigation and the Suzano partnership. Relative to the prior analysis, the focus moved from the initial portfolio and productivity setup toward execution of innovation, premiumization and the IFP joint venture.

Guidance delta

Guidance sentiment was maintained; the supplied analysis does not identify a new numerical guidance change.

Key takeaways

  • Management described a seventh consecutive quarter of volume-plus-mix growth.
  • Diaper innovation and premiumization were identified as drivers of share gains and mix improvement.
  • Promotional activity was shifted toward Q4 to support trial of new innovations.
  • Management expects tariff mitigation and the Suzano fiber partnership to reduce cost volatility and support gross-margin expansion.
  • Long-term gross-margin and operating-margin targets remained in place.

Management priorities

  • Roll out additional diaper innovations and continue premiumization across tiers.
  • Expand digital sales and club-channel growth.
  • Complete the IFP joint venture and integrate related synergies.
  • Use the Suzano partnership to stabilize fiber costs.
  • Continue toward long-term gross- and operating-margin milestones.

Follow KMB with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
KMB EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q1 '24 estimate $1.63 Q1 '24 actual $2.01, beat Q2 '24 estimate $1.71 Q2 '24 actual $1.96, beat Q3 '24 estimate $1.70 Q3 '24 actual $1.83, beat Q2 '25 estimate $1.67 Q2 '25 actual $1.92, beat Q3 '25 estimate $1.75 Q3 '25 actual $1.82, beat Q4 '25 estimate $1.81 Q4 '25 actual $1.86, beat Q1 '26 estimate $1.93 Q1 '26 actual $1.97, beat Q2 '26 estimate $2.01 Q2 '26 actual $1.80, miss Q3 '26 estimate $1.61 Q4 '26 estimate $1.75 Q1 '27 estimate $1.81
Show 1 more >

Analyst Consensus ?

ConsensusHold31 ratings
Bullish1032.2%
Neutral1858.1%
Bearish39.7%

Analyst 52W Price Targets

$97.43Previous close
$99Low
$133.03Average
$174High

Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 1, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
B of A Securities Buy BuyMaintainSep 25, 2026
Piper Sandler Overweight OverweightMaintainSep 11, 2026
Wells Fargo Equal Weight Equal WeightMaintainSep 10, 2026
UBS Neutral NeutralMaintainAug 5, 2026
TD Cowen Hold HoldMaintainAug 5, 2026
Barclays Equal Weight Equal WeightMaintainJul 21, 2026
Deutsche Bank Hold HoldMaintainMar 30, 2026
Citigroup Sell SellMaintainJan 14, 2026
BNP Paribas Exane Neutral NeutralMaintainDec 1, 2025
Argus Research Buy HoldUpgradeNov 13, 2025
Morgan Stanley Equal Weight Equal WeightMaintainNov 4, 2025
Evercore ISI Group In Line OutperformDowngradeNov 4, 2025
JP Morgan Neutral NeutralMaintainOct 31, 2025
RBC Capital Outperform OutperformMaintainApr 23, 2025
HSBC Hold HoldMaintainApr 24, 2024
Goldman Sachs Buy BuyMaintainApr 24, 2024
Bernstein Market Perform UnderperformUpgradeOct 12, 2023
Berenberg Hold HoldMaintainApr 26, 2023
Jefferies Hold BuyDowngradeJan 4, 2023
Bank of America Buy NeutralUpgradeSep 27, 2019
Atlantic Equities Neutral UnderweightUpgradeJul 24, 2019
Macquarie Outperform NeutralUpgradeApr 23, 2019
Societe Generale Hold BuyDowngradeAug 15, 2018
B. Riley FBR Neutral NeutralMaintainMay 5, 2018
Argus Buy HoldUpgradeMay 5, 2018
CLSA Underperform OutperformDowngradeOct 26, 2016
B. Riley Securities Neutral NeutralMaintainJan 26, 2016
B. Riley Neutral NeutralMaintainJan 26, 2016
BMO Capital Outperform Market PerformUpgradeDec 23, 2014
Credit Suisse Underperform UnderperformMaintainApr 22, 2013
Bank oferica Buy BuyMaintainApr 23, 2012
Show less

Named analyst price targets

Upside is calculated against the persisted previous close $97.43. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
GuggenheimAnalyst unavailable$120$97.22 +23.2%Sep 25, 2026
Piper SandlerAnalyst unavailable$118$98.48 +21.1%Sep 11, 2026
UBSPeter Grom$116$110.11 +19.1%Aug 5, 2026
BarclaysAnalyst unavailable$115$108.48 +18.0%Jul 21, 2026
UBSAnalyst unavailable$115$108.13 +18.0%Jul 16, 2026
Piper SandlerAnalyst unavailable$121$104.28 +24.2%Jun 17, 2026
UBSAnalyst unavailable$106$97.4 +8.8%Apr 29, 2026
BarclaysLauren Lieberman$99$97.1 +1.6%Apr 14, 2026
Wells FargoAnalyst unavailable$100$97 +2.6%Apr 8, 2026
Wells FargoAnalyst unavailable$110$109.41 +12.9%Feb 17, 2026
UBSPeter Grom$110$100.51 +12.9%Jan 28, 2026
BarclaysAnalyst unavailable$102$99.64 +4.7%Jan 16, 2026
UBSAnalyst unavailable$107$98.86 +9.8%Jan 14, 2026
Wells FargoAnalyst unavailable$105$98.52 +7.8%Jan 5, 2026
BNP ParibasAnalyst unavailable$110$109.84 +12.9%Dec 1, 2025
Morgan StanleyAnalyst unavailable$125$99.79 +28.3%Nov 4, 2025
Evercore ISIAnalyst unavailable$120$102.27 +23.2%Nov 4, 2025
BarclaysAnalyst unavailable$132$119.71 +35.5%Nov 3, 2025
RBC CapitalNik Modi$162$121.45 +66.3%Oct 28, 2025
UBSPeter Grom$130$120.8 +33.4%Oct 8, 2025
Piper SandlerMichael Lavery$145$123.23 +48.8%Oct 2, 2025
BarclaysAnalyst unavailable$131$124.34 +34.5%Oct 1, 2025
Piper SandlerKorinne Wolfmeyer$156$133.4 +60.1%Apr 23, 2025
Wells FargoAnalyst unavailable$140$140.71 +43.7%Mar 28, 2025
BarclaysAnalyst unavailable$144$140.56 +47.8%Mar 27, 2025
CFRAAna Garcia$151$137.75 +55.0%Oct 22, 2024
Deutsche BankSteve Powers$142$137.34 +45.7%Jul 24, 2024
Piper SandlerKorrine Wolfmeyer$174$140.79 +78.6%Jul 11, 2024
RBC CapitalNik Modi$165$133.3 +69.4%Jun 3, 2024
BarclaysLauren Lieberman$136$137.78 +39.6%Apr 25, 2024
Deutsche BankSteve Powers$132$127.27 +35.5%Mar 28, 2024
HSBCAlejandro Zamacona$146$127.27 +49.9%Mar 28, 2024
Evercore ISIJavier Escalante$150$127.27 +54.0%Mar 28, 2024
Piper SandlerKorinne Wolmeyer$152$127.27 +56.0%Mar 27, 2024
Morgan StanleyDara Mohsenian$153$128.98 +57.0%Aug 7, 2023
JefferiesStephanie Wissink$150$135.66 +54.0%Apr 6, 2023
J.P. MorganAnalyst unavailable$124$136.74 +27.3%Jan 13, 2023
JefferiesAnalyst unavailable$139$137.11 +42.7%Jan 4, 2023
Deutsche BankAnalyst unavailable$123$135.48 +26.2%Dec 6, 2022
Wells FargoAnalyst unavailable$120$112.54 +23.2%Oct 3, 2022
UBSAnalyst unavailable$142$132.12 +45.7%Jul 27, 2022
Deutsche BankAnalyst unavailable$134$132.14 +37.5%Jul 27, 2022
BarclaysAnalyst unavailable$124$128.34 +27.3%May 23, 2022
BarclaysLauren Lieberman$129$142.05 +32.4%Apr 28, 2022
Deutsche BankSteve Powers$138$143.92 +41.6%Apr 25, 2022
Morgan StanleyAnalyst unavailable$137$141.64 +40.6%Apr 25, 2022
Wells FargoAnalyst unavailable$135$138.51 +38.6%Apr 25, 2022
J.P. MorganAndrea Faria Teixeira$120$139.66 +23.2%Apr 25, 2022
Goldman SachsJason English$124$125.03 +27.3%Apr 3, 2022
UBSPeter Grom$138$136.25 +41.6%Jan 27, 2022
BNP ParibasJeff Stent$148$141.86 +51.9%Jan 11, 2022
Deutsche BankStephen Powers$130$130.98 +33.4%Oct 26, 2021
HSBCRobert Price$131$135.43 +34.5%Sep 9, 2021
Show less

Track every rating change on KMB the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates in two segments, North America and International Personal Care. The North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related products under the Huggies, Pull-Ups, Goodnites, Kotex, Poise, Depend, Kleenex, Scott, Cottonelle, Viva, Wypall , and other brand names.…

Historical context

All KMB earnings

Consumer Defensive peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the KMB recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-01T10:46:11.901921+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-01T10:46:11.898963+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-01. For educational purposes only; not investment advice.